Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI set to revolutionize MS diagnosis and monitoring

NCT ID NCT06280755

Knowledge-focused Sponsor: icometrix Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study gathers health data from 7,000 people with multiple sclerosis (MS) and related conditions. The goal is to use this information to train artificial intelligence (AI) tools that can help doctors diagnose MS earlier and predict how the disease will progress. No new treatments are being tested; instead, researchers are building a large database to improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 7,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include patients with a confirmed diagnosis of MS (Thompson et al., 2018), CIS, RIS, NMOSD (Wingerchuck et al., 2015), or MOGAD (Banwell et al., 2023). No other specifications are included. We envision a database that captures the diversity and heterogeneity of the population, in order to address factors influencing disease worsening that have not been investigated yet or have only been investigated to a very limited extent in previous studies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Patients must have a confirmed diagnosis of MS, NMOSD, MOGAD, CIS or RIS. * Patient (or patient's legal representative) has previously signed and dated an informed consent form (ICF) for the secondary use of their data, or assent form. Alternatively, the secondary use of the patient's data is allowed following Institutional Review Board (IRB)/Ethical Committee (EC) approval in accordance with national and local subject privacy regulations. Exclusion criteria: * Patients under 18 years of age will be excluded. * Other unspecified reasons that, in the opinion of the Investigator or Joint Steering Committee, make the patient unsuitable for participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinically isolated syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disease Progression multiple sclerosis myelin oligodendrocyte glycoprotein antibody-associated disease neuromyelitis optica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinically isolated syndrome Multiple sclerosis Myelin oligodendrocyte glycoprotein antibody-associated disease Nmo spectrum disorder Radiologically isolated syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ERC Charité - Universitätsmedizin Berlin

    RECRUITING

    Berlin, State of Berlin, 131256, Germany

  • General University Hospital Prague

    RECRUITING

    Prague, Praha 2, 128 00, Czechia

  • Katholisches Klinikum Bochum - St. Joseph-Hospital

    RECRUITING

    Bochum, Bochum, 44791, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.